Skip to Main Content

Paper Details

Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
Nat Cancer
22
2022
Author NameAffiliation
Ido AmitWeizmann Institute of Science
  • 1 - 1

Datasets

Release 1.2